Structure of Plasmodium vivax N-myristoyltransferase with inhibitor IMP-1088
Author Information
Author(s): Alex Mendez, Cydni Bolling, Shane Taylor, Stanley Makumire, Bart Staker, Alexandra Reers, Brad Hammerson, Stephen J. de Mayclin, Jan de Abendroth, Donald D. de Lorimer, Thomas E. de Edwards, Edward W. Tate, Sandhya Subramanian, Andrew S. Bell, Peter J. Myler, Oluwatoyin A. Asojo, Graham Chakafana
Hypothesis
Can IMP-1088 effectively inhibit Plasmodium vivax N-myristoyltransferase (PvNMT) to aid in antimalarial therapy?
Conclusion
The study presents the ternary structure of PvNMT in complex with IMP-1088 and myristoyl-CoA, highlighting its potential as a target for new malaria treatments.
Supporting Evidence
- The study provides a detailed structure of PvNMT, which is crucial for developing new malaria treatments.
- IMP-1088 is shown to bind similarly to both PvNMT and human NMT, suggesting potential for drug repurposing.
- The research highlights the importance of targeting PvNMT to combat malaria effectively.
Takeaway
Scientists studied a protein from a malaria parasite and found a new way to block it, which could help create better medicines against malaria.
Methodology
The study involved crystallizing the PvNMT protein and determining its structure using X-ray crystallography.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website